US 12,275,724 B2
Processes and intermediates for the preparation of soluble guanylate cyclase stimulators
Debra Jane Wallace, Lexington, MA (US); Fenger Zhou, Cambridge, MA (US); Yuguang Wang, Cambridge, MA (US); Takashi Nakai, Newton, MA (US); Vishnu Vardhan Reddy Karnati, Sudbury, MA (US); Wayne C. Schairer, Westboro, MA (US); William Kissel, Cambridge, MA (US); Song Xue, Newton, MA (US); and Ahmad Hashash, Southborough, MA (US)
Assigned to Cyclerion Therapeutics, Inc., Cambridge, MA (US)
Filed by Cyclerion Therapeutics, Inc., Cambridge, MA (US)
Filed on May 22, 2024, as Appl. No. 18/671,182.
Application 18/671,182 is a division of application No. 18/140,966, filed on Apr. 28, 2023, granted, now 12,030,874.
Application 18/140,966 is a division of application No. 17/497,352, filed on Oct. 8, 2021, granted, now 11,708,361, issued on Jul. 25, 2023.
Application 17/497,352 is a division of application No. 16/961,109, granted, now 11,274,096, issued on Mar. 15, 2022, previously published as PCT/US2019/013060, filed on Jan. 10, 2019.
Claims priority of provisional application 62/615,678, filed on Jan. 10, 2018.
Claims priority of application No. PCT/CN2018/076982 (WO), filed on Feb. 22, 2018.
Prior Publication US 2024/0391911 A1, Nov. 28, 2024
Int. Cl. C07D 413/14 (2006.01); C07D 403/04 (2006.01); C07D 413/12 (2006.01)
CPC C07D 413/14 (2013.01) [C07D 403/04 (2013.01); C07D 413/12 (2013.01); C07B 2200/13 (2013.01)] 4 Claims
 
1. A compound of formula (3) or (4):

OG Complex Work Unit Chemistry
wherein R1 is phenyl, or a 5 to 6-membered heteroaryl ring; optionally substituted with up to three instances independently selected from the group consisting of halogen or methyl; wherein said 5 or 6-membered heteroaryl ring contains up to 3 ring atoms selected from the group consisting of N, S or O.